The company will not receive any proceeds from the sale of the shares by the selling stockholders. Invest with Confidence: Follow TipRanks' Top ...

Vor Biopharma Inc. (NYSE:VOR – Get Free Report) has received an average rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Seven investment ...

Vor announced it entered into a securities purchase agreement for a private investment in public equity financing. The company expects to generate about $55.6 million in gross proceeds.

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of ...

Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical ...

A Buddha Air flight with 76 people on board made an emergency VOR landing at Tribhuvan International Airport in Kathmandu after experiencing a flame-out in its left engine.

Vor Bio (NASDAQ:VOR) shares soared more than 20% in Friday pre-market trading, after it said that it has entered into a securities purchase agreement for a private investment in public equity ...

Vor shares are higher lower on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing. Vor Biopharma reveals ...

Vor Bio, a clinical-stage cell and genome engineering company, has appointed Mr. Erez Kalir to its Board of Directors, creating a new seat following a recent private investment in public equity ...